ACADIA Pharmaceuticals Announces Appointment of David C. Furlano, Ph.D., as Vice President, Regulatory Affairs

January 9, 2006

SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today announced the appointment of David C. Furlano, Ph.D., as Vice President, Regulatory Affairs.

"Dr. David Furlano brings to ACADIA more than 15 years of regulatory affairs experience. His broad experience of leading regulatory efforts for early and late-stage drug candidates, marketed products, and across therapeutic areas, including CNS indications, will be a great asset as our discovery and development pipeline continues to mature," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA.

Dr. Furlano joins ACADIA from Vical, where he served as Executive Director, Regulatory Affairs and had managerial and strategic responsibility for all aspects of regulatory affairs. Prior to Vical, he was Executive Director, Regulatory Affairs and Compliance at Amylin Pharmaceuticals, where he led the U.S. regulatory affairs group. Dr. Furlano also has held regulatory positions at Ligand Pharmaceuticals, Abbott Laboratories and Parke-Davis Pharmaceuticals. Earlier in his career, he worked as a reviewer at the U.S. Food and Drug Administration and as a research scientist at the National Institutes of Health. Dr. Furlano received a Ph.D. degree in Medicinal Chemistry and Natural Products from the University of Iowa and a Bachelor of Science degree from the University of Connecticut.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for CNS disorders. ACADIA currently has four drug programs in clinical development as well as a portfolio of preclinical and discovery assets directed at large unmet medical needs, including schizophrenia, Parkinson's disease, neuropathic pain, and glaucoma. All of the drug candidates in ACADIA's product pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA's corporate headquarters is located in San Diego, California and it maintains research and development operations in both San Diego and Malmo, Sweden.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related to the progress and timing of ACADIA's drug discovery and development programs and related trials. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery, development and commercialization, collaborations with others, and litigation. For a discussion of these and other factors, please refer to ACADIA's annual report on Form 10-K for the year ended December 31, 2004 filed with the United States Securities and Exchange Commission as well as other subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and ACADIA undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871